Saved local watchlist · Deprioritization mentions · sorted by registry update date
Candidate queue
877 active trial–asset records · showing latest 25 · no composite ranking
An ingestion window is pending. Refresh resumes the next page.
| Asset / trial | Sponsor / phase | Status / stopping reason | Independent scores | Source |
|---|---|---|---|---|
| DiltiazemNCT02025465 | CAMC Health SystemPHASE4 | TERMINATED Low enrollment and PI retired. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| MetoprololNCT02025465 | CAMC Health SystemPHASE4 | TERMINATED Low enrollment and PI retired. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-10 |
| BevacizumabNCT06329570 | NaviFUS CorporationPHASE1, PHASE2 | SUSPENDED FDA reviewing | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| LumasonNCT06329570 | NaviFUS CorporationPHASE1, PHASE2 | SUSPENDED FDA reviewing | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| IberdomideNCT06179888 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Scheduled Interim Monitoring | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| Nab-paclitaxelNCT05685602 | National Cancer Institute (NCI)PHASE1 | SUSPENDED Drug Supply Issues | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| Gemcitabine HydrochlorideNCT05685602 | National Cancer Institute (NCI)PHASE1 | SUSPENDED Drug Supply Issues | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| EmavusertibNCT05685602 | National Cancer Institute (NCI)PHASE1 | SUSPENDED Drug Supply Issues | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| RifampicinNCT06191692 | Freundeskreis Für Internationale Tuberkulosehilfe e.VPHASE3 | WITHDRAWN Lack of Rifapentine | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| RifapentineNCT06191692 | Freundeskreis Für Internationale Tuberkulosehilfe e.VPHASE3 | WITHDRAWN Lack of Rifapentine | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| IsoniazidNCT06191692 | Freundeskreis Für Internationale Tuberkulosehilfe e.VPHASE3 | WITHDRAWN Lack of Rifapentine | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| glenzocimabNCT06437431 | Fondation Ophtalmologique Adolphe de RothschildPHASE2, PHASE3 | WITHDRAWN The study was discontinued following the cessation of the company's activities, which resulted in the investigational medicinal product no longer being available. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| Baricitinib 4 MGNCT05858515 | Vanderbilt University Medical CenterPHASE3 | WITHDRAWN This submission for the pilot study has been withdrawn as the full trial opened under a different NCT number before participants enrolled in the pilot. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| TamsulosinNCT01203371 | Apsen Farmaceutica S.A.PHASE3 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| NaftopidilNCT01203371 | Apsen Farmaceutica S.A.PHASE3 | WITHDRAWN Reason not reported | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-09 |
| HP 13C PyruvateNCT03952598 | National Cancer Institute (NCI)PHASE2 | SUSPENDED Study on hold pending possible updates with the team. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| Active CannabisNCT04596644 | New York State Psychiatric InstitutePHASE2 | SUSPENDED In response to quality assurance and compliance concerns, OHRP issued an FWA restriction on NYSPI research that included a pause of human research as of June 23, 2023. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| MethotrexateNCT05691478 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Extend the observation period for current patients | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| Doxorubicin HydrochlorideNCT05691478 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Extend the observation period for current patients | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| CisplatinNCT05691478 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Extend the observation period for current patients | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| Cabozantinib S-malateNCT05691478 | National Cancer Institute (NCI)PHASE2, PHASE3 | SUSPENDED Other - Extend the observation period for current patients | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential20 Operational complexity80 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| anti-CD19 CAR-T cellsNCT06792344 | The Children's Hospital of Zhejiang University School of MedicinePHASE1 | SUSPENDED temporarily suspended due to no new subjects at present | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potential75 Operational complexity25 Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| VolenrelaxinNCT06598631 | Eli Lilly and CompanyPHASE2 | WITHDRAWN Study was terminated due to a lack of foreseeable clinical benefit in the proposed chronic kidney disease population, following the termination of a related heart failure study that demonstrated no benefit in an overlapping patient group. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihoodUnknown Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| MetforminNCT05580250 | Eli Lilly and CompanyPHASE1 | WITHDRAWN The sponsor made a business decision to withdraw the trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
| SimvastatinNCT05580250 | Eli Lilly and CompanyPHASE1 | WITHDRAWN The sponsor made a business decision to withdraw the trial. | ScienceUnknown SafetyUnknown Strategic-abandonment likelihood75 Cheap-to-truth potentialUnknown Operational complexityUnknown Licensing attractivenessUnknown | Registry evidence2026-09-08 |
Recent ingestion runs
| Source | Studies seen | Candidate writes | Status / finished |
|---|---|---|---|
| pubmed | 240 | 100 | finished2026-09-21T03:58:28.397783+00:00 |
| pubmed | 0 | 0 | failed2026-09-21T03:48:59.232056+00:00 |
| sec | 0 | 0 | finished2026-09-21T03:48:59.212906+00:00 |
| ClinicalTrials.gov | 300 | 258 | partial2026-09-21T03:48:59.189357+00:00 |
| ClinicalTrials.gov | 300 | 305 | Legacy run2026-09-21T03:45:47.341408+00:00 |
| ClinicalTrials.gov | 300 | 348 | Legacy run2026-09-21T03:38:48.082427+00:00 |